Ad
related to: covid antibody treatment
Search results
Doctor hails launch of cancer vaccine as a 'new age' in fight against disease
Daily Express· 7 days agoA GP of 30 years has hailed the trial of an innovative cancer vaccine as a “significant...
Small Business - The Roanoke-Chowan News-Herald | The Roanoke-Chowan News-Herald
Roanoke-Chowan News-Herald· 7 days agoInvivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced that Timothy Lee will be appointed Invivyd’ ...
Trying to solve the ‘cruel mystery,’ lupus
Post-Bulletin· 7 days agoWhile pregnant with her second child, Shamiere Schwahn noticed something was off. The symptoms she experienced, Schwahn said, were assumed to be because...
Small Business - Picayune Item | Picayune Item
The Picayune Item· 3 days agoGHENT, Belgium, June 04, 2024 (GLOBE NEWSWIRE) -- ExeVir Bio, a biotech company developing robust heavy chain-only antibody therapies for broad protection against infectious ...
TECVAYLI® (teclistamab-cqyv) shows sustained deep and durable responses in patients with relapsed or...
Valley City Times Record· 4 days ago"With the longest follow-up of any bispecific antibody, teclistamab demonstrates continued deep and durable responses observed in patients with relapsed or refractory multiple ...
Triplet Notches Survival Win in Heavily Pretreated DLBCL
MedPage Today· 5 days agoBenefit with BV plus lenalidomide-rituximab seen in those who relapsed after CAR-T or transplant
What’s wrong with your brain? It could come down to what you need more of each night
Miami Herald via Yahoo News· 2 days ago“There is no cure for Alzheimer’s disease, but it is a new era of treatment,” said Curiel Cid. The...
Improved Outcomes With Subcutaneous Amivantamab in NSCLC
Medscape· 5 days agoSubcutaneous amivantamab plus lazertinib may offer a survival benefit over intravenous administration, alongside dramatically reduced administration times, a new study suggests.
First Patient Gets mRNA Bowel Cancer Vaccine In England, With Thousands More Coming
IFLScience· 7 days agoThe initiative, called the Cancer Vaccine Launch Pad, aims to get more patients onto trials of mRNA...
Gilead and Arcus Announce Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of...
Morningstar· 5 days agoGilead and Arcus Announce EtrumadenantPlus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-line Metastatic Colorectal Cancer – In Cohort B of the ARC-9 mCRC Study, Etrumadenant ...